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What is already known about this subject
• In June 2013, a series of changes to the marketing aut
children below the age of 12 years and in children unde
• No previously published studies of the impact of introd
children in the EU were identified.
• Joinpoint regression analysis is a tool to study drug util
Pharmacoepidemiol Drug Saf. 2019;1–11.Abstract
Purpose: In June 2013, following recommendations from the World Health
Organization (WHO) and Food and Drug Administration (FDA), the European
Medicines Agency agreed updates to the codeine product information regarding
use for pain in children younger than 12 years and children undergoing tonsillectomy
or adenoidectomy (TA) for obstructive sleep apnoea. This study was conducted
to (a) assess effectiveness of these measures on codeine prescribing in the
“real‐world” setting and (b) test feasibility of a study using a common protocol by
regulators with access to databases.
Methods: The study was performed using BIFAP (Spain), CPRD (UK), and IMS®
Disease Analyzer (France and Germany) databases. Prescribers included general
practitioners (GPs) (France and UK), GPs and paediatricians together (Spain), and
GPs, paediatricians, and ear, nose, and throat (ENT) specialists separately (Germany).
Between January 2010 and June 2015, prevalence of codeine prescribing was
obtained every 6 months, and a time series analysis (joinpoint) was performed.
Codeine prescribing within ±30 days of TA was also identified. Furthermore, doses,
durations, and prior prescribing of other analgesics were investigated.
Results: Over the 5‐year period, codeine prescribing decreased in children younger
than 12 years (by 84% in France and Spain, 44% in GP practices in Germany, and 33%
in the United Kingdom). The temporal pattern was compatible with the regulatory
intervention in France and the United Kingdom, whereas a decrease throughout the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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horisation for codeine products in the EU were introduced, including recommendations to not use codeine for treatment of pain in
rgoing tonsillectomy or adenoidectomy (TA) due to obstructive sleep apnoea.
uced risk minimisation measures (RMM) for codeine for treatment of pain in children on the subsequent prescribing of codeine in
ization trends over time and identify time points when significant changes in trend occur.
wileyonlinelibrary.com/journal/pds 1
2 HEDENMALM ET AL.study period was seen in Germany and Spain. Decreased prescribing associated with
TA was suggested in ENT practices in Germany.
Conclusions: Codeine prescribing for children decreased in line with introduced
regulatory measures. Multidatabase studies assessing impact of measures by EU
regulators are feasible.
KEYWORDS
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• Prescribing of codeine for treatment of pain in children
below the age of 12 years decreased in all four
countries with a temporal pattern that was compatible
with an impact of the RMM in the United Kingdom and
in France. There was also evidence of decreased
prescribing of codeine after the introduced RMM for
children undergoing TA in ear, nose, and throat
practices in Germany. The findings of reduced exposure
to codeine in children at increased risk of toxicity are
reassuring, but further follow‐up of prescribing of
codeine in children is warranted to determine if codeine
prescribing in children continues to decrease or levels off.
• It was also shown that collaborative risk minimisation
effectiveness studies using a common protocol by
regulators with direct access to electronic health record
databases are feasible.1 | INTRODUCTION
Codeine is an opium alkaloid, which has been approved for pain relief, as
an antitussive agent, and as an antidiarrhoeal agent in individual countries
in the European Union (EU). It is available as a single ingredient (plain
codeine) and in combinationwith other substances. Codeine is converted
in the body via the enzyme CYP2D6 into morphine, which is responsible
for the analgesic effect of codeine.1,2 Themost severe risk of codeine use
is respiratory depression, associated with morphine toxicity.1
Concerns over the safe and effective use of codeine for pain relief in
children have been expressed for a number of years.3-9 In March 2011,
the World Health Organization (WHO) deleted codeine from its list of
essential medicines in children3 and in 2012, published guidelines on
the pharmacological treatment of persisting pain in children, where use
of codeine was no longer recommended.4 In August 2012, the United
States Food and Drug Administration (FDA) communicated that codeine
use in certain children after tonsillectomy or adenoidectomy (TA)
may lead to rare but life‐threatening adverse events or death.5,6
Subsequently, in April 2017, the FDA contraindicated use of codeine in
all children below the age of 12 years.10
In October 2012, the European Medicines Agency (EMA)
Pharmacovigilance Risk Assessment Committee (PRAC) started a
review of the use of codeine for treatment of pain in children.11,12 This
led, in June 2013, to the PRAC recommending risk minimisation
measures (RMM) including restrictions on its use13 and communications
about the safety concerns by national authorities.14-22 Updated
guidelines for analgesic use in children have since been published, in line
with the regulatory communications.23-25
The restrictions of use included that codeine should only be used
in children 12 years or older for pain that cannot be relieved by other
analgesics such as paracetamol or ibuprofen alone. Also, the lowest
effective dose should be used for the shortest period of time in these
children. Contraindications were introduced for pain relief in children
of all ages undergoing TA for obstructive sleep apnoea and in patients
who are CYP2D6 ultra‐rapid metabolisers as they have an increased
risk of morphine toxicity due to faster than normal conversion of
codeine to morphine.
National competent authorities (NCAs) in the Members States, the
EMA, and the European Commission collaborate to regulate medicines
in the EU. The monitoring of the safety of medicines has been
enhanced as a result of the new European pharmacovigilancelegislation, which serves to proactively manage the risk of marketed
drugs in a sustainable life‐cycle benefit‐risk management approach.26
Within this legislation, the PRAC is responsible both for implementing
RMM and for overseeing their effectiveness.27 With this in mind, a
key objective of the present study was to proactively assess the
impact of the introduced measures on codeine prescribing for pain in
“real‐world” clinical practice. This was to be done by focusing on time
trends for prevalence of use of codeine for pain in children younger
than 12 years and in those undergoing TA. As prescribing practices
across the EU may differ between individual Member States, the study
was to be conducted in databases representing a number of EU
countries to gain insight into possible variation in impact across the
EU. The opportunity would also be taken to use the study to evaluate
a model for collaboration within a best evidence strategy to support
decision making by the EU medicines regulators.28 Regulators with
access to electronic health records (EHR) databases were invited to
participate in the study. To this end, the Spanish and United Kingdom
NCAs (AEMPS, Spanish Agency for Medicines and Medical Devices
and MHRA, Medicines and Healthcare products Regulatory Authority,
respectively) collaborated with EMA, who had access to data for
HEDENMALM ET AL. 3France and Germany as “a Best Evidence pilot group.” Hence, the
study represents a population of around 260 million EU citizens.
Drug utilisation studies of use of codeine for pain in children before
and after regulatory action have been previously performed in Norway
and the United States.29-31 Significant drops in use have been identified.
Surveys to prescribers in Sweden and the United States have also
provided evidence of reduced prescribing of codeine in children.32,33
Recognised possible therapeutic alternatives to codeine for treatment
of pain in children include, eg, paracetamol, nonsteroidal anti‐inflammatory
drugs (NSAIDs), coxibs, and opioid analgesics such as dihydrocodeine,
tramadol, morphine, tapentadol, or oxycodone.23-25,34-44 However,
investigating whether a potential decrease in prescribing of codeine was
associated with a shift in prescribing to other analgesics was considered
outside the scope of the study.2 | METHODS
2.1 | Setting
The agreed study time period was between 1 January 2010 and 31
December 2014 (Spain) or 30 June 2015 (UK, France, and Germany)
in line with the frequency of updates of the databases.
The study was conducted in the BIFAP database in Spain, the CPRD
database in the United Kingdom, and the IMS® Disease Analyzer
databases (IMS®) in France and Germany. All of the included databases
collect anonymised EHR from general practitioners (GPs). BIFAP45
also includes data from paediatricians, which together with GPs are
considered as primary care physicians, and were analysed together.
IMS® Germany includes data from a range of specialist physicians. Data
from GPs, paediatricians, and ear, nose, and throat (ENT) specialists in
IMS® Germany were analysed separately. Practices in BIFAP include
around 16% of the Spanish population45 and practices in CPRD include
around 7% of the UK population.46 Around 2% and 3% of all GP
practices in France and Germany, respectively, are included in IMS®.
Patients in BIFAP, CPRD, and IMS® France are broadly representative of
the total population in terms of age and gender,46,47 whereas children are
underrepresented among GP patients in IMS® Germany.47,48 For coding
of symptoms and diagnoses, BIFAP uses the International Classification
of Primary Care (ICPC‐2) and ICD‐9, CPRD uses Read Codes and IMS®
uses ICD 10. More information about the databases included in the study,
and the study population, is provided in Appendix S1.2.2 | Study design
Patients included in the study were those younger than 18 years with
at least 1 year of follow‐up in the database. One year of follow‐up was
not required for children younger than 1 year.
For the purpose of this study, RMM were considered to be
introduced on 28 June 2013, which was the date of endorsement of
the PRAC recommendations by the Coordination Group for Mutual
Recognition and Decentralised procedures for Human Medicinal
Products (CMDh).49 National communications took place subsequentto this and changes to the product information were to be implemented
in all EU Member States by 1 October 2013.50
Within the time period of the study, all codeine‐containing
products in Germany and Spain were prescription‐only medicines. In
France, preparations containing less than 30 mg of codeine did not
require a prescription by a physician,51 and in the United Kingdom,
some low‐dose forms of combinations including codeine were
available without prescription.
A common study protocol focused on codeine used for pain was
agreed on 25 November 2015 by a group established by the PRAC.
In order to capture use of codeine for treatment of pain, the exposures
of interest included products containing codeine alone (ATC code
R05DA04), codeine in combination with an analgesic or NSAID (ATC
classes N02A and N02B), and codeine in combination with an
analgesic and an antihistamine (ATC class N02C). Products containing
codeine in combination with menthol, sympathomimetics, antitussives,
expectorants, antihistamines (without an analgesic or NSAID), herbal
cough ingredients, or an antispasmodic agent or antidiarrhoeal were
excluded. Oral solutions and solid oral formulations of plain codeine
products were evaluated separately. As products containing plain
codeine may be indicated for both pain and cough, a review of patient
records was performed to determine the indication more accurately
and to exclude prescriptions for nonpain indications.
In BIFAP, indications linked to the prescription for any of the
codeine‐containing products in the study were reviewed, and
diagnoses related to an indication of pain, or a respiratory or digestive
condition, were identified. In children where a linked indication could
not be allocated to any of the three indication categories, diagnoses
within 14 days prior to the prescription were also reviewed in order
to allocate the prescription to one of the defined indication categories.
Of the total of 61 302 children with a prescription for one of the
codeine‐containing products, 1923 (3.1%) were considered to have
received codeine for treatment of pain and were included in further
analyses. Children without an allocated indication for treatment
(6.1%; n = 3767) along with children considered to have received
codeine for a nonpain indication (90.7%; n = 55 612), mostly respiratory
indications (88.7%; n = 54 381), were excluded from the study.
In CPRD, treatment of pain was considered for codeine in
combination with an analgesic or NSAID, codeine in combination with
an analgesic and antihistamine, and prescriptions of plain codeine
where no record of cough could be identified within 14 days of the
prescription. The majority of children with a prescription for one of
the codeine‐containing products, 19 591 of 19 969 (98.1%) were
considered to have received at least one prescription of codeine for
treatment of pain and were included in further analyses.
In IMS®, treatment of pain was considered for codeine in
combination with an analgesic or NSAID, codeine in combination with
an analgesic and antihistamine, and prescriptions of plain codeine where
no record of cough and no diagnosis likely to indicate cough could be
identified within 14 days of the prescription. In IMS® France, the
majority of children with a prescription for one of the codeine‐containing
products, 3207 of 3385 (94.7%) were considered to have received at
least one prescription of codeine for the treatment of pain and were
4 HEDENMALM ET AL.included in further analyses. Corresponding proportions for GP practices,
paediatric practices, and ENT practices in IMS® Germany were 59.3%
(5672/9571), 53.1% (7574/14 252), and 71.8% (333/464) of children,
respectively.2.3 | Analysis
The number of childrenwith a codeine prescriptionwas calculated by age
group (younger than 12 y and 12‐17 y), gender, and half‐yearly (every 6
mo) time periods. Key results included prevalence of prescribing of
codeine for pain and use of codeine within a period of ±30 days of a
TA surgical procedure. Information about how TA was identified within
the databases is provided in Appendix S1. TA was identified among
children with a codeine prescription. In ENT practices in IMS®Germany,
TA was also identified among all children. For information about how
daily doses and durations were calculated, see also Appendix S1.
The proportion of children that had been prescribed another analgesic
(ie, not containing codeine) within a period of 90 days up to the time of
the codeine prescription was also calculated.2.3.1 | Analysis of changes in prescribing trends
To evaluate whether changes in prescribing associated with the RMM
were statistically significant, a post hoc analysis of prescribing trends
for children younger than 12 years was performed using joinpoint
regression analysis with log‐linear model.52-54 Joinpoint regression
determines changes in prescribing trend, called joinpoints, and a new
joinpoint is added only if there is a statistically significant improvement
in the fit of the model. Permutation tests using Monte Carlo methods
were used to determine the minimum number of joinpoints required
to provide an adequate fit to the data. A significance level of 5% was
used to assess the need for each extra joinpoint, starting from zeroTABLE 1 Descriptive overview of children 0‐17 y with a prescription for
BIFAP CPRD
No. of children 0‐17 y included in demographics 1915 17689
Females (%) 1097 (57.3) 11448 (58.4
Children 0‐11 y (%) 415 (21.7) 1702 (9.6)
Children 12‐17 y (%) 1499 (78.3) 15987 (90.4
Plain codeine solution (%) 375 (19.6) 779 (4.4)
Plain codeine solid formulation (%) 25 (1.3) 3229 (18.3
Combination with analgesic/NSAID (%) 1514 (79.1) 12983 (73.4
Combination with analgesic and antihistamine (%) 1 (0.1) 1092 (6.2)
Other analgesics within 90 d before codeine (%) 595 (31.1) 1290 (7.3)
Note. Children included in demographics were all children that had codeine us
half‐year (BIFAP), or all children with at least 90 d of follow‐up prior to the code
patient could contribute to more than one type of codeine product. In IMS® (F
group and to more than one type of codeine product. For details about other a
Abbreviations: ENT, ear, nose, and throat practice; GP, general practice; IMS®,
aOwn calculations, based on IMS® Disease Analyzer (France, Germany).joinpoints. The timepoint for the joinpoint (with 95% confidence
intervals) can then be compared with the dates of the interventions.553 | RESULTS
3.1 | Prevalence of use of codeine for treatment
of pain
The most commonly prescribed codeine formulation in France,
Spain, and the United Kingdom was codeine in combination with an
analgesic or NSAID, whereas in Germany, it was a liquid oral
formulation of plain codeine (Table 1). Codeine in combination with
both an analgesic and an antihistamine was effectively only prescribed
in the United Kingdom (Table 1).
A numerical decrease in overall prescribing of codeine between the
start and end of the study period could be seen in all countries, although
there was no observed decrease in prescribing of plain codeine in solid
oral formulation or codeine in combination with both an analgesic and
an antihistamine (Table 2). The decrease was more pronounced in the
age group below 12 years with little evidence of a decrease in the use
of codeine in children 12 to 17 years, except in Spain (Table 2). The
prevalence of prescribing of codeine at the start of the study period
was less in children below the age of 12 years compared with that of
children 12 to 17 years, except for ENT practices in Germany.
Prescribing trends in the age group below 12 years, in which
treatment with codeine for pain was no longer indicated following
June 2013, are shown in Figure 1. Prescribing trends in all children
are shown in Figure 2.
In children below 12 years, initial increases in prescribing between
2010 and 2012 were seen in France and the United Kingdom,
followed by decreases from 2013 onwards. In contrast, a decrease in
prescribing could be seen in Spain already between 2011 and 2012,codeine during the study period
IMS® Francea
IMS® Germany
GPa
IMS® Germany
PAEDa
IMS® Germany
ENTa
2983 4526 6558 205
) 1580 (53.0) 2355 (52.0) 3334 (50.8) 118 (57.6)
1571 (52.7) 1718 (38.0) 4870 (74.3) 127 (62.0)
) 1427 (47.8) 2889 (63.8) 1829 (27.9) 79 (38.5)
1391(46.6) 3081 (68.1) 5766 (87.9) 144 (70.2)
) 22 (0.7) 605 (13.4) 499 (7.6) 23 (11.2)
) 1601 (53.7) 992 (21.9) 343 (5.2) 41 (20.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
742 (24.9) 1803 (39.8) 2863 (43.7) 57 (27.8)
e registered in a half‐year and no codeine use registered in the previous
ine prescription (CPRD, IMS® France, IMS® Germany). In CPRD, the same
rance, Germany), the same patient could contribute to more than one age
nalgesics within 90 d before codeine, see Appendix S1.
IMS® Disease Analyzer; NA, not applicable; PAED, paediatric practice.
TABLE 2 Prevalence (per 10 000) of prescribing of codeine in children 0‐17 y at the start and end of the study period
Time
Period BIFAP CPRD
IMS®
Francea
IMS® Germany
GPa
IMS® Germany
PAEDa
IMS® Germany
ENTa
All children 0‐17 y Start 4.4 28.4 29.2 81.8 37.0 11.4
End (% change) 1.4 (−68%) 22.7 (−20%) 14.6 (−50%) 64.3 (−21%) 29.4 (−21%) 6.1 (−47%)
Children 0‐11 y Start 1.9 3.8 25.0 72.9 36.0 12.2
End (% change) 0.3 (−84%) 2.6 (−33%) 3.9 (−84%) 40.6 (−44%) 23.8 (−34%) 4.8 (−61%)
Children 12‐17 y Start 11.5 73.4 38.8 90.7 41.6 9.3
End (% change) 4.2 (−63%) 71.8 (−2%) 35.0 (−10%) 84.0 (−7%) 47.9 (+15%) 8.3 (−11%)
Female children 0‐17 y Start 3.8 37.0 29.5 81.5 38.2 13.9
End (% change) 1.1 (−71%) 30.6 (−17%) 18.1 (−39%) 70.9 (−13%) 31.6 (−17%) 8.1 (−42%)
Male children 0‐17 y Start 5.0 20.2 29.1 82.0 35.8 9.1
End (% change) 1.6 (−68%) 15.1 (−25%) 11.3 (−61%) 58.0 (−29%) 27.2 (−24%) 4.3 (−53%)
Plain codeine solution 0‐17 y Start 1.5 1.1 15.3 54.3 32.67 7.8
End (% change) 0.1 (−93%) 0.6 (−51%) 3.0 (−80%) 41.4 (−24%) 25.85 (−21%) 4.2 (−46%)
Solid formulation plain codeine 0‐17 y Start 0.0 4.3 0.0 7.7 2.0 1.2
End (% change) 0.0 (NA) 4.6 (+6%) 0.2 (+∞%) 10.5 (+36%) 2.8 (+44%) 1.1 (−6%)
Combination with analgesic/
NSAID 0‐17 y
Start 2.9 21.6 14.1 20.4 2.5 2.7
End (% change) 1.3 (−55%) 16.2 (−25%) 11.2 (−81%) 13.5 (−34%) 0.7 (−71%) 0.8 (−72%)
Combination with analgesic and
antihistamine 0‐17 y
Start 0.0 2.1 0.0 0.0 0.0 0.0
End (% change) 0.0 (NA) 2.6 (+20%) 0.0 (NA) 0.0 (NA) 0.0 (NA) 0.0 (NA)
Note. Start of the study period was defined as 1 January to 30 June 2010. End of the study period was defined as 1 January to 30 June 2015 in CPRD and
in IMS (France, Germany), and as 1 July to 31 December 2014 in BIFAP.
Abbreviations: ENT, ear, nose, and throat practice; GP, general practice; IMS®, IMS® Disease Analyzer; NA, not applicable; PAED, paediatric practice.
aOwn calculations, based on IMS® Disease Analyzer (France, Germany).
FIGURE 1 A‐F, Six‐monthly prevalence (per 10 000) of codeine for the treatment of pain in children 0‐11 y in (A) Francea, (B‐D) Germanya,
(E) Spain, and (F) the United Kingdom. (A) IMS® France (top left corner). (B) IMS® Germany GP (middle top). (C) IMS® Germany PAED (top
right corner). (D) IMS® Germany ENT (bottom left corner). (E) BIFAP (middle bottom). (F) CPRD (bottom right corner) ENT = ear, nose, and throat
practice, GP = general practice, IMS® = IMS® Disease Analyzer, PAED = paediatric practice. aOwn calculations, based on IMS® Disease Analyzer
(France, Germany) [Colour figure can be viewed at wileyonlinelibrary.com]
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FIGURE 2 A‐F, Six‐monthly prevalence (per 10 000) of codeine for the treatment of pain in children 0‐17 y in (A) Francea, (B‐D) Germanya,
(E) Spain, and (F) the United Kingdom. (A) IMS® France (top left corner). (B) IMS® Germany GP (middle top). (C) IMS® Germany PAED (top
right corner). (D) IMS® Germany ENT (bottom left corner). (E) BIFAP (middle bottom). (F) CPRD (bottom right corner) ENT = ear, nose, and throat
practice, GP = general practice, IMS® = IMS® Disease Analyzer, PAED = paediatric practice. aOwn calculations, based on IMS® Disease Analyzer
(France, Germany) [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Joinpoint analyses of six‐monthly prescribing trends of codeine for treatment of pain in children 0‐11 y
No. of Joinpoints Joinpoint Location (Lower CL, Upper CL) Slope Annual Percent Change (Lower CL, Upper CL)
BIFAP 0 NA 1 −16.6 (−21.7, −11.3)
CPRD 1 2013 H1 (2012 H1 − 2013 H2) 1
2
2.7 (−1.1, 6.6)
−14.7 (−21.3, −7.6)
IMS® Francea 1 2012 H2 (2012 H1 − 2013 H2) 1
2
5.3 (−0.3, 11.2)
−32.8 (−39.3, −25.6)
IMS® Germany GPa 0 NA 1 −5.4 (−8.5, −2.2)
IMS® Germany PAEDa 0 NA 1 −3.8 (−7.7, 0.2)
IMS® Germany ENTa 0 NA 1 −10.4 (−16.9, −3.3)
Note. A log linear joinpoint regression model was selected. Significant annual percent changes are highlighted in bold.
Abbreviations: CL, 95% confidence limit; ENT, ear, nose, and throat practice; GP, general practice; IMS®, IMS® Disease Analyzer; NA, not applicable;
PAED, paediatric practice; H1, January to June; H2, July to December.
aOwn calculations, based on IMS® Disease Analyzer (France, Germany).
6 HEDENMALM ET AL.and this continued into 2013. There were large fluctuations in
prescribing in Germany that made it difficult to assess when a
decrease in prescribing started.
Joinpoint analysis of prescribing in children below 12 years
identified a change in prescribing trend in France and the United
Kingdom. No change in prescribing trend was detected in Germany
or Spain (Table 3 and Figure 3).
3.2 | Use of codeine within 30 days of undergoing TA
In Spain, no child was recorded as having received a prescription
for codeine within 30 days of undergoing TA, and in GP practices
in Germany, only two children had a prescription for codeinewithin 30 days of undergoing TA. The proportion of children with a
prescription for codeine that had undergone TA within 30 days of
the codeine prescription in France, in paediatric and ENT practices in
Germany, and in the United Kingdom is shown inTable 4. There seems
to be a trend that use of codeine within 30 days of undergoing TA
has decreased since 2012, at least in ENT practices in Germany.
Only a small proportion (varying from 2% to 7%) of the children
that had received codeine within 30 days of undergoing a TA had a
diagnosis of sleep apnoea recorded prior to the TA. No child with a
diagnosis of sleep apnoea was prescribed codeine within 30 days of
the TA after 2013.
A total of 8242 TA procedures were identified in ENT practices in
Germany. The proportion of children undergoing TA that had received
FIGURE 3 A‐F, Joinpoint analyses of six‐monthly prescribing trends for codeine for treatment of pain in children 0‐11 y in (A) Francea, (B‐D)
Germanya, (E) Spain, and (F) the United Kingdom. (A) IMS® France (top left corner). (B) IMS® Germany GP (middle top). (C) IMS® Germany
PAED (top right corner). (D) IMS® Germany ENT (bottom left corner). (E) BIFAP (middle bottom). (F) CPRD (bottom right corner). ENT = ear,
nose, and throat practice, G = general practice, IMS® = IMS® Disease Analyzer, PAED = paediatric practice, Proportion = proportion of children
with a codeine prescription. The dots represent the six‐monthly prevalences. The lines represent the selected joinpoint model. aOwn calculations,
based on IMS® Disease Analyzer (France, Germany) [Colour figure can be viewed at wileyonlinelibrary.com]
HEDENMALM ET AL. 7codeine within 30 days decreased over time from 0.4%‐0.6% in
2010‐2011 to 0.1%‐0.3% in 2012‐2013 to 0.0% in 2014‐2015.
Codeine was more often prescribed within the first 7 days of
undergoing TA compared with 8 to 30 days after the TA, and up to
30 days before the TA.3.3 | Doses, durations, and use of other analgesics
over time
There was no observed decrease in median durations or doses over
time and also no evidence of an increase in the proportion of children
that had received a prescription for another analgesic within 90 days
of the codeine prescription over time; please see Appendix S1 and
Tables A1 to A3.4 | DISCUSSION
4.1 | Summary of results
The study investigated changes in prescribing of medicines containing
codeine for pain in children taking account of RMM introduced in 2013.
A general decrease in prescribing of codeine for treatment of pain
over the study period was found in children below the age of 12 yearsin all of the countries. Changes in prescribing trend that were
temporarily compatible with the introduced RMM were identified in
France and the United Kingdom, but the wide confidence intervals
could not rule out that the rate was declining already before the
RMM, eg, at the timepoint when the PRAC review was announced.
The decreasing prescribing in children below the age of 12 years in
Germany and Spain already before the introduced RMM in Europe
may indicate that prescribers were aware of concerns with the use
of codeine in children, eg, from earlier WHO or FDA communications
or other clinical guidelines that are outside the scope of medicines
regulators. Nevertheless, findings suggest an overall more limited
impact on prescribing of codeine for pain in children below the age
of 12 years during the first 2 years after the RMM in the United
Kingdom and in GP and paediatric practices in Germany compared
with ENT practices in Germany and practices in France and Spain,
based on a total decrease in prescribing from the start to the end of
the study period of 33%, 34%, and 44% in the United Kingdom,
German GP, and German paediatric practices vs 61%, 84%, and 84%
in German ENT practices and French and Spanish practices.
There was a trend that use of codeine within 30 days of
undergoing TA decreased since 2012, at least in German ENT
practices. Numbers were small, and TA procedures may have been
underrecorded in GP and paediatric practices, with some uncertainty
around the exact date of the TA procedure.
TABLE 4 Number of children with use of codeine within 30 days of
undergoing tonsillectomy or adenoidectomy (TA) (percent of children
with a codeine prescription in parenthesis)
Database (Total
No. of Children
With a Codeine
Prescription)
CPRD
(n = 19 591)a
IMS®
France
(n = 3207)b
IMS®
Germany
PAED
(n = 7574)b
IMS®
Germany
ENT
(n = 333)b
All children 0‐17 ya 429 (2.2%) 28 (0.9%) 14 (0.2%) 35 (10.5%)
Children 0‐11 y 135 (7.5%) 25 (1.5%) 14 (0.2%) 32 (15.6%)
Children 12‐17 y 294 (1.6%) 3 (0.2%) 0 (0.0%) 3 (2.3%)
Female children
0‐17 y
298 (2.3%) 15 (0.9%) 8 (0.2%) 19 (10.2%)
Male children 0‐17 y 131 (1.9%) 13 (0.9%) 6 (0.2%) 16 (11.0%)
Oral solution plain
codeine
227 (1.5%) 21 (1.4%) 14 (0.2%) 23 (10.0%)
Solid oral
formulation plain
codeine
2 (0.1%) 0 (0.0%) 0 (0.0%) 2 (5.0%)
Combination with
analgesic/
NSAID
132 (16.6%) 7 (0.4%) 0 (0.0%) 10 (14.7%)
Combination with
analgesic and
antihistamine
73 (1.9%) NA NA NA
1st HY 2010 53 (2.1%) 4 (1.1%) 3 (0.3%) 7 (14.9%)
2nd HY 2010 59 (2.3%) 1 (0.3%) 1 (0.1%) 5 (12.8%)
1st HY 2011 33 (1.3%) 3 (0.7%) 2 (0.2%) 9 (16.7%)
2nd HY 2011 61 (2.3%) 3 (0.8%) 3 (0.3%) 6 (11.5%)
1st HY 2012 50 (2.0%) 7 (1.7%) 3 (0.3%) 4 (6.6%)
2nd HY 2012 52 (2.0%) 3 (0.7%) 1 (0.1%) 2 (7.1%)
1st HY 2013 27 (1.2%) 3 (0.8%) 1 (0.1%) 1 (3.2%)
2nd HY 2013 40 (1.9%) 1 (0.4%) 0 (0.0%) 1 (4.3%)
1st HY 2014 24 (1.3%) 1 (0.5%) 0 (0.0%) 0 (0.0%)
2nd HY 2014 21 (1.1%) 2 (1.3%) 0 (0.0%) 0 (0.0%)
1st HY 2015 12 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Note. In BIFAP, no child received codeine within 30 d of undergoing
tonsillectomy or adenoidectomy (TA). In IMS® Germany GP, only two
children received codeine within 30 d of undergoing TA. Data from BIFAP
and IMS® Germany GP are therefore not displayed in the table.
Abbreviations: ENT, ear, nose, and throat practice; GP, general practice;
HY, half‐year; IMS®, IMS® Disease Analyzer; NA, not applicable; PAED,
paediatric practice.
aIn CPRD, eight children had a diagnosis of sleep apnoea prior to the TA.
bOwn calculations, based on IMS® Disease Analyzer (France, Germany).
One child in IMS® France, IMS® Germany PAED and IMS® Germany
ENT, respectively, had a diagnosis of sleep apnoea prior to the TA.
8 HEDENMALM ET AL.Children treated for pain with codeine represented only 3.2% of all
children (up to 9.3% of children if prescriptions without an identified
indication are also allocated to the pain indication) with a prescription
for one of the codeine products in Spain compared with 94.7% in France,
51.3% to 71.8% in Germany, and 98.1% in the United Kingdom, which
illustrates possible differences in indications for which a drug may beprescribed across countries. On the other hand, treatment of pain was
not identified in the same way across all databases, being more stringent
in Spain as a result of direct recording of the treatment indication in the
BIFAP database. Considering the less strict identification of pain in the
other databases, resulting in inclusion of all prescriptions for one of the
codeine products except plain codeine prescriptions with an identified
diagnosis indicating cough, an apparent lower impact of the RMMmight
have been expected in France, Germany, and the United Kingdom
compared with Spain. However, due to the very small prevalence of
use of codeine for pain in children in Spain, there was little power to
analyse changes in prescribing over time.4.2 | Feasibility
The study was based on a high‐level common study protocol. Analyses
were then customised to the specific databases and health care
systems and differed slightly between databases. For example, the
indication for treatment was specifically coded and could be obtained
directly only in the BIFAP database in Spain, whereas doses and
durations were available only in a minority of individual prescriptions
in IMS® Germany, making it particularly difficult to estimate the
treatment duration in Germany. Considering that the study focused
on changes over time rather than absolute values, these slight
differences in analyses, while considered acceptable overall, were also
acknowledged to make direct comparisons more complex.4.3 | Limitations
In Germany and Spain, prescribing was already decreasing before the
introduced RMM, and no changes in prescribing trends associated
with the RMM were identified. This might have been due to
insufficient power to investigate a step change or steeper decline in
an already decreasing prescribing trend. In Spain, power was already
low due to a very low baseline level of prescribing. We also included
only a limited follow‐up time after the RMM to study changes in
prescribing. It is plausible that a longer follow‐up time could have
further detected changes in prescribing, linked also to the impact of
a second EU‐wide review of codeine for cough and cold in children
that started in April 2014 and concluded in March 2015. The outcome
of this review was largely in line with the previous recommendations
for codeine when used for pain relief.
The purchase of codeine without a prescription (over the counter
[OTC] pharmacy sales), which may have taken place in France and
the United Kingdom during the study period, could also not be
quantified, although the focus of our study was on prescribing by
health care professionals. Codeine is now restricted to prescription‐only
medicine in France.51 Additionally, hospital use of codeine was not
included in the study. This is relevant for underestimation of the results
on use of postoperative codeine within 30 days of undergoing TA.
Due to differences between databases and health care systems and a
stricter definition of use of codeine for treatment of pain in the BIFAP
database, the absolute values for prevalence were not comparable.
Instead, changes over time were analysed.
HEDENMALM ET AL. 9Only EU countries with access to EHR databases with information
on prescribing could participate in the study. Due to regional
differences in prescribing, eg, a predominant prescribing of liquid oral
formulation of plain codeine in Germany vs codeine in combination
with an analgesic or NSAID in the other countries, findings cannot
be extrapolated to countries outside of the study.
4.4 | Implications
This studywas performed in collaboration between EMAand twoNCAs
in the context of proactive management of the risks of marketed
drugs.27 Existing decreasing trends in prescribing of codeine for
treatment of pain in children below the age of 12 years, and in children
undergoing TA, at the time of the introduction of RMM are reassuring,
even if they may relate to earlier publications or safety communications
and cannot be directly attributed to the introduced RMM. Further
follow up of the decrease in prescribing may be warranted considering
that the RMM aimed not only to decrease but to ultimately eliminate
prescribing of codeine for pain in children below the age of 12 years.
As codeine has subsequently been contraindicated also for treatment
of cough and cold in children below the age of 12 years, a decrease
can now be expected for all codeine products and indications. Whether
the reduced prescribing of codeine for treatment of pain in children
below the age of 12 years was associated with a shift in prescribing to
other analgesics or whether prescribing of other analgesics also
decreased during the study period was not evaluated. This will instead
be addressed in a separate study. The databases included in the study
have been found to be broadly representative of their underlying
populations,46-48 comprising a total of around 260 million EU citizens
(around 50% of the total EU population), although the exact extent to
which prescription estimates from the databases are unbiased in
relation to their total underlying population is not known.
A recent systematic review of studies that have measured the
impact of regulatory interventions found that only a limited number
of regulatory interventions had been evaluated.56 Time series analysis
was themostwidely used study design (66.0%), including regression‐based
approaches to determine statistical significance in 42.5% of all studies
with joinpoint regression in only 5.9% of all studies.56
4.5 | Conclusion
The current study of the impact of introduced RMM suggested that
prescribing of codeine for treatment of pain in children below the
age of 12 years decreased over time in all included countries and that
in France and the United Kingdom, prescribing changed around the
time of the introduced RMM. There was also a more specific
suggestion that prescribing in ENT practices in Germany to children
undergoing TA decreased after the introduction of the RMM.
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